Biocodex has its own integrated Research and Development center in Compiegne (France). Internal research requires in-depth knowledge of all our medicines and health products, which enables us to evaluate their impact and carry out projects relating to therapeutic innovation.
Biocodex R&D mission
The multidisciplinary proficiency of our chemists, pharmacologists, microbiologists and clinical researchers provides a 360-degree approach to our products. More than 45 highly qualified scientists work in the following departments:
- Chemistry, from the synthesis of active ingredients to analytical approaches;
- Microbiology, entirely dedicated to research into microbiota and probiotics;
- Pharmacology, the aim of which is to improve knowledge about our drugs and perform preclinical evaluations;
- Clinical Research, which leads clinical studies to evaluate efficacy and safety of our products.
This combined expertise enables us to develop new chemical methods of synthesis which respect the environment, guarantee the pharmaceutical quality of our active ingredients, explore mechanisms of action of drugs, search for new indications and innovate with new pharmaceutical forms.
Main areas of research
1Microbiota and Probiotics
Biocodex is a pioneer in this domain, with its probiotic yeast, Saccharomyces boulardii CNCM I-745®, that has been evaluated in a huge number of preclinical and clinical studies. Our scientists have extended their research beyond gut microbiota and now work on a large spectrum of other microbiota investigations, using the most sophisticated investigative methods.
Our R&D team carries out intensive research on women-specific disorders, with a particular interest for pathologies associated with vaginal microbiota dysbiosis. This knowledge is key to providing new health products in this field.
3Central Nervous System and Orphan Diseases
Biocodex has great expertise in psychiatric and neurological disorders, specifically epilepsy. This originates from when the Biocodex research unit discovered and developed stiripentol (Diacomit®). This orphan antiepileptic drug is indicated in a rare and very severe type of epilepsy. Since then, it has been given marketing authorization in Europe, Japan, Canada, the U.S.A, Australia, Switzerland and Argentina. Biocodex is still investing in this essential drug through an intensive program of preclinical and clinical research.
Biocodex R&D partnerships
Our researchers work in close collaboration with numerous academic teams around the world on common fields of interest, principally gastroenterology, gynecology, and the central nervous system. Biocodex R&D Center has long-established partnerships with eminent French academic teams from research organizations such as INRA, INSERM and CNRS. As scientific progress today is truly global, we are also proud to collaborate with physicians and scientists from Canada, Ecuador, Germany, Italy, Mexico, Monaco, Morocco, Russia, Thailand and the United States, for example.
Want to know more?
Biocodex has invested in start-ups since 2016 and become a key player in the French biotech ecosystem. We focus mainly on companies developing medical unmet needs and innovative therapeutics from probiotics, or microbial strains that are beneficial to health. With its long-term approach and industrial expertise, Biocodex is recognized as a valuable partner by CEOs, project owners and traditional investors, such as fund managers. Biocodex is always looking to support new meaningful projects.